Illumina Extends Management Team, Appoints Sam A. Samad as Senior Vice President and Chief Financial Officer
December 07 2016 - 06:30AM
Business Wire
Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of
Sam A. Samad, Senior Vice President and Chief Financial Officer. He
will join the company on January 6th, 2017.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20161207005502/en/
Sam Samad (Photo: Business Wire)
“I look forward to welcoming Sam to Illumina’s executive team,”
said Marc Stapley, Executive Vice President and Chief
Administrative Officer of Illumina. “Sam’s global experience in
leading large finance organizations at major corporations, coupled
with his healthcare experience in sales and general management, has
prepared him well to help us accomplish our mission. Personally, I
look forward to welcoming Sam to my team and handing over the CFO
reigns to him.”
Sam will be responsible for the company’s finance, accounting,
investor relations, internal audit and treasury functions. He joins
Illumina from Cardinal Health where he held several senior
leadership positions including most recently Senior Vice President
and Corporate Treasurer, with leadership responsibility for
Cardinal Health's China business. Sam was previously Senior Vice
President and Chief Financial Officer for the pharmaceutical
segment, and Vice President, Healthcare Supply Chain Services. He
also previously held finance roles at Eli Lilly and PepsiCo Inc.
Sam holds a BBA degree from the American University of Beirut in
Lebanon and an MBA from McMaster University in Hamilton,
Canada.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
Forward-Looking StatementsThis release contains
forward-looking statements that involve risks and uncertainties.
Examples of forward-looking statements include, but are not limited
to, statements we make regarding the expected availability dates
for new products and services and FDA submission dates and
intentions for certain products and services. Important factors
that could cause actual results to differ materially from those in
any forward-looking statements include challenges inherent in
developing, manufacturing, and launching new products and services,
and the other factors that are detailed in our filings with the
Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in
public conference calls, the date and time of which are released
beforehand. We do not intend to update any forward-looking
statements after the date of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161207005502/en/
Illumina, Inc.Investors:Rebecca Chambers,
858-255-5243rchambers@illumina.comorMedia:Eric Endicott,
858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2023 to Mar 2024